This disclosure provides methods and compositions for the production of engineered eukaryotic cells wherein the production of both glutaminase isozymes (Gls and Gls2) and asparaginase (Aspg) is reduced such that ammonia production is almost entirely eliminated before stationary phase and substantially decreases it over the course of culture, even when grown in glutamine-containing medium.
The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
3.
PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate-specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
The present invention discloses halimide and plinabulin and structural analogues and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen halimide-like molecules as pharmaceutically active compounds.
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 403/02 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
5.
Asparaginase based selection system for heterologous protein expression in mammalian cells
A non-naturally occurring cell comprising an inoperative genomic asparaginase (Aspg) gene and an inoperative glutamine synthetase (Gs) gene, wherein the cell has been transfected with a controllably expressed gene encoding an enzyme having asparaginase activity, a controllably expressed gene encoding an enzyme having glutamine synthetase activity, and a controllably expressed gene encoding a heterologous protein of interest.
The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 49/04 - Préparations de contraste pour rayons X
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
7.
GLYMPHATIC DELIVERY BY MANIPULATING PLASMA OSMOLARITY
The present invention discloses isoquinolines and 1H-2-Benzopyranes and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen isoquinoline- and 1H-2-Benzopyran-like molecules as pharmaceutically active compounds.
A61K 31/4741 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. dérivés du tubocurarane, noscapine, bicuculline
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
10.
GAMMA STIMULATION PULSING LIGHT SOURCE SYSTEM WITH DOSAGE ADJUSTMENT FOR GAZE ANGLE
Gamma brain stimulation for preventing or treating Alzheimer's disease or sleeping disorders using light or sound is known. A strobing 40 Hz light source has been shown to cause positive effects due to the stimulation. It is an advantage to know the actual dosage of light that enters the person's eyes in order to understand the relationship between dosage and effectiveness. A camera is used to detect the subject's gaze angle, distance, pupil diameter and any other factors that affect the light power that enters the eye. A target dosage is first determined by a medical worker, such as to determine the effects of the exact same dosage on a group persons, such as Alzheimer's patients. With deviations of gaze angle, distance, and pupil size from the ideal, the effective dosage is decreased. The disclosed system adjusts the actual dosage, such as session duration, based on such factors so that the final dosage received by the person is consistent and meets the target dosage.
The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
12.
ELECTRON TUBE, IMAGING DEVICE AND ELECTROMAGNETIC WAVE DETECTION DEVICE
In an electron tube (1), the meta-surface (S) emits an electron in response to an incidence of the electromagnetic wave. The first and second electrodes (81, 82) are spaced away from each other, and apply potentials different from each other to the meta-surface (S). A holder (30) is disposed in the housing (10) and holds the electron emitter (20). A first conductive line (83) of the meta-surface (S) is electrically connected to the first electrode (81). A second conductive line (84) of the meta-surface (S) is spaced away from the first conductive line (83), and is electrically connected to the second electrode (82). The first conductive line (83) extends from the first electrode (81) to the second conductive line (84). The second conductive line (84) extends from the second electrode (82) to the first conductive line (83).
H01J 40/16 - Tubes à décharge photo-électrique n'impliquant pas l'ionisation d'un gaz à cathode photo-émissive, p. ex. cellule photo-électrique alcaline
There is provided an encryption device that is secure against a side channel attack, and can suppress a processing load. The encryption device includes a data encryption part in which at least part of a plurality of round functions for successively performing encryption processing on an input value is tabulated to be encrypted using a white-box model in which input/output values of the round function is able to be recognized from the outside. Each of the round functions includes a tabulated encryption function for encrypting an input value using a black-box model in which the input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside, and the encryption function is updated with a random number.
G06F 21/54 - Contrôle des utilisateurs, des programmes ou des dispositifs de préservation de l’intégrité des plates-formes, p. ex. des processeurs, des micrologiciels ou des systèmes d’exploitation au stade de l’exécution du programme, p. ex. intégrité de la pile, débordement de tampon ou prévention d'effacement involontaire de données par ajout de routines ou d’objets de sécurité aux programmes
G06F 7/58 - Générateurs de nombres aléatoires ou pseudo-aléatoires
G06F 21/55 - Détection d’intrusion locale ou mise en œuvre de contre-mesures
Embodiments disclosed herein include novel nucleic acid-guided nucleases, novel guide nucleic acids, and novel targetable nuclease systems, and methods of use. In some embodiments, engineered non-naturally occurring nucleic acid-guided nucleases, can be used with known guide nucleic acids in a targetable nuclease system. In certain embodiments, targetable nuclease systems can be used to edit targeted genomes of humans and other species. In some embodiments, methods include, but are not limited to, recursive genetic engineering and trackable genetic engineering methods.
The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR- Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
This invention concerns a photo-cathode for a vacuum system, wherein the photo-cathode is configured for receiving electromagnetic radiation having an incoming wavelength and for emitting electrons in response thereto. The photo-cathode comprises a conducting structure having a geometry, the geometry comprising a tip section. The tip section is adapted to provide field enhancement, β, when the conducting structure is illuminated with the electromagnetic radiation, wherein β is greater than about 102. The photo-cathode further comprising a substrate, the substrate being or comprising a dielectric substrate, the substrate supporting the conducting structure.
An electron tube includes a housing that is internally held in a vacuum and has a window transmitting an electromagnetic wave, an electron emitting unit that is disposed in the housing and has a meta-surface emitting electrons in response to incidence of the electromagnetic wave, an electron multiplying unit that is disposed in the housing and multiplies the electrons emitted from the electron emitting unit, and an electron collecting unit that is disposed in the housing and collects the electrons multiplied by the electron multiplying unit. The window contains at least one selected from quartz, silicon, germanium, sapphire, zinc selenide, zinc sulfide, magnesium fluoride, lithium fluoride, barium fluoride, calcium fluoride, magnesium oxide, and calcium carbonate.
H01J 40/16 - Tubes à décharge photo-électrique n'impliquant pas l'ionisation d'un gaz à cathode photo-émissive, p. ex. cellule photo-électrique alcaline
The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
19.
NEUROTROPHIC FACTOR PROTEIN CONJUGATES AND RELATED EMBODIMENTS
ClostridialClostridial neurotoxin. Vectors, host cells, and methods of use and making are also described. Pharmaceutical compositions comprising the protein conjugates described herein are used to provide neuroprotection and treat neurodegenerative diseases and neuron damage amongst other things.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
There is provided an encryption device to ensure strong security without using a random number in a white-box model. The encryption device includes: an encryption part configured to encrypt an input value using a black-box model in which input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside; and a key generation part configured to encrypt the input value to the encryption part to generate a cryptographic key of the encryption part using a white-box model in which the input/output value and the intermediate value are able to be recognized from the outside.
H04L 29/06 - Commande de la communication; Traitement de la communication caractérisés par un protocole
G09C 1/00 - Appareils ou méthodes au moyen desquels une suite donnée de signes, p. ex. un texte intelligible, est transformée en une suite de signes inintelligibles en transposant les signes ou groupes de signes ou en les remplaçant par d'autres suivant un système préétabli
H04L 9/06 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p. ex. système DES
Method of separation of of a radiometal ion from a target metal ion, comprising a first liquid-liquid extraction step in which an organic phase comprising an extractant and an interfacial tension modifier is mixed with an aqueous phase comprising the radiometal ion and the target metal ion in order that the radiometal ion is at least partially transferrred to the organic phase, followed by a first phase separation step, wherein the phase separation is carried out in flow comprising the use of a microfiltration membrane to separate the phases based on the interfacial tension between the phases such that a permeate phase passes through the membrane and a retentate phase does not.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
A method is provided for calibrating a microfluidic system comprising, which method is based on using beads having a structure based on DNA origami, wherein said structure comprises a predetermined number of fluorophores. Furthermore, methods for determining the level of an antigen using microfluidics calibrated using fluorescent microbeads as provided herein. Also, methods are provided for determining the presence or state of a haematological disease by calibrated a microfluidics system.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01F 25/00 - Test ou étalonnage des appareils pour la mesure du volume, du débit volumétrique ou du niveau des liquides, ou des appareils pour compter par volume
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
25.
TREATMENT OF EPILEPSY WITH PLINABULIN OR HALIMIDE OR DIKETOPIPERAZINE DERIVATIVES
The present invention discloses halimide and plinabulin and structural analogues and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen halimide- like molecules as pharmaceutically active compounds.
A61K 31/4741 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. dérivés du tubocurarane, noscapine, bicuculline
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
[Problem] To ensure strong security in a white-box model without the use of random numbers. [Solution] This encryption device is provided with: an encryption unit which encrypts input values by means of a black-box model, in which input and output values can be recognized from the outside and intermediate values cannot be recognized from the outside; and a key generation unit which encrypts input values of the encryption unit by means of a white-box model, in which input and output values and intermediate values can be recognized from the outside, and generates an encryption key of the encryption unit.
G09C 1/00 - Appareils ou méthodes au moyen desquels une suite donnée de signes, p. ex. un texte intelligible, est transformée en une suite de signes inintelligibles en transposant les signes ou groupes de signes ou en les remplaçant par d'autres suivant un système préétabli
28.
ENCRYPTION DEVICE, ENCRYPTION METHOD, DECRYPTION DEVICE, AND DECRYPTION METHOD
[Problem] To provide an encryption calculation which is secure against side channel attacks and which can keep down processing loads. [Solution] This encryption device is provided with a data encryption unit that performs encryption with a white box model in which at least some of multiple rounding functions for sequentially performing encryption processing on input values are tabulated and in which the input and output values of the rounding functions can be recognized from the outside. Each of the aforementioned rounding functions has a tabulated encryption function which encrypts input values in a black box model in which the input and output values can be recognized from the outside and intermediate values cannot be recognized from the outside, and the encryption functions are updated by means of random numbers.
G09C 1/00 - Appareils ou méthodes au moyen desquels une suite donnée de signes, p. ex. un texte intelligible, est transformée en une suite de signes inintelligibles en transposant les signes ou groupes de signes ou en les remplaçant par d'autres suivant un système préétabli
29.
METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCAEMIA
REGION HOVEDSTADEN (CAPITAL REGION OF DENMARK) (Danemark)
TECHNICAL UNIVERSITY OF DENMARK (Danemark)
Inventeur(s)
Lyngbye Wendt, Sabrina
Ranjan, Ajenthen
Madsen, Henrik
Nørgaard, Kirsten
Bagterp Jørgensen, John
Abrégé
Methods and medical uses for determining a dose for a glucagon bolus for administration to patients with diabetes for treating mild or moderate hypoglycaemia, while reducing the risk of, or avoiding, rebound hyperglycaemia are described. This work is based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon to develop an optimum glucagon dosing regimen for treatment of mild or moderate hypoglycaemia depending on ambient insulin levels, while reducing the risk of, or avoiding, rebound hyperglycaemia, for example as may occur when an overly large dose of glucagon is administered to a patient having a hypoglycaemic episode.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
30.
DEVELOPMENT OF INJECTABLE FIDUCIAL MARKERS FOR IMAGE GUIDED RADIOTHERAPY WITH DUAL MRI AND CT VISIBILITY
Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ∼40% larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1 :1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Ti contrast enhancement (T1 ∼900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy
A61K 49/04 - Préparations de contraste pour rayons X
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
32.
MULTICORE FIBER, AND MULTICORE FIBER TAPE USING SAME
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
TECHNICAL UNIVERSITY OF DENMARK (Danemark)
Inventeur(s)
Sasaki Yusuke
Takenaga Katsuhiro
Saitoh Kunimasa
Morioka Toshio
Nooruzzaman Md.
Abrégé
A multicore fiber (1A) includes a plurality of cores (11A, 11B) arranged in a matrix, and single cladding (21) surrounding the cores (11A, 11B). An outer shape of a cross-section perpendicular to the longitudinal direction of the cladding (21) is formed into a noncircular shape having the smallest diameter in a prescribed direction and having no recess. Two or more cores (11A, 11B) are arranged in a prescribed direction while a number of cores (11A, 11B) outnumbering the number of the cores arranged in the prescribed direction are arranged in a direction perpendicular to the prescribed direction. The multicore fiber (1A) is bent in a prescribed direction for use.
G02B 6/04 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage formés par des faisceaux de fibres
33.
METHOD FOR DETERMINING A DEADZONE ANGLE OF A BACKLASH IN A MECHANICAL DRIVE-TRAIN SYSTEM, METHOD FOR CONTROLLING A DRIVE MOTOR CONTROLLER AS WELL AS DRIVE-TRAIN SYSTEM
The invention relates to a method for determining a deadzone angle (δ) of a backlash in a mechanical drive-train system (1), wherein the drive train-system (1) comprises a drive motor (2), a load (3) and a shaft (4) for connecting the drive motor (2) with the load (3), the method comprising the steps: estimating an interconnection torque (Tl) in the deadzone, determining the deadzone angle (δ) depending on the interconnecting torque (Tl) by means of an adaptive estimator, wherein in the adaptive estimator the backlash is modelled in terms of a variable stiffness (KBL) of the shaft (4).
G05B 19/404 - Commande numérique [CN], c.-à-d. machines fonctionnant automatiquement, en particulier machines-outils, p. ex. dans un milieu de fabrication industriel, afin d'effectuer un positionnement, un mouvement ou des actions coordonnées au moyen de données d'un programme sous forme numérique caractérisée par des dispositions de commande pour la compensation, p. ex. pour le jeu, le dépassement, le décalage d'outil, l'usure d'outil, la température, les erreurs de construction de la machine, la charge, l'inertie
The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body. In another embodiment the composition is a liquid before administration and has the ability to transform into a crystalline or amorphous solid after administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
35.
Encryption device, encryption method, decryption device, and decryption method
There is provided an encryption device including a data encryption unit configured to conduct encryption on the basis of a white box model in which at least a part of a plurality of round functions for sequentially conducting encryption processing on an input value is tabulated, and input and output values of the round function are recognizable from an outside. The plurality of round functions each have an encryption function that is tabulated and encrypts an input value in a black box model in which input and output values are recognizable from the outside and an intermediate value is not recognizable from the outside.
H04L 9/00 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité
H04L 9/06 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p. ex. système DES
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japon)
TECHNICAL UNIVERSITY OF DENMARK (Danemark)
Inventeur(s)
Sasaki Yusuke
Takenaga Katsuhiro
Saitoh Kunimasa
Morioka Toshio
Abrégé
Provided is a multicore fiber containing a plurality of cores, wherein when the multicore fiber is bent to form a curve with a diameter of 280 mm, the optical propagation loss in a mode one order higher than an optical mode used for information transmission in the optical wavelength band used for the information transmission is set between 1 dB/m and 0.02 dB/m inclusive. Thus, unnecessary light in a higher order mode can be sufficiently attenuated within propagation of 1 km. Thereby, even if unnecessary light is created in a higher order mode at a contact point between fibers, the unnecessary light in the higher order mode can be sufficiently attenuated before the next contact point.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
38.
PIPERAZINE INHIBITORS OF BACTERIAL GYRASE AND TOPOISOMERASE IV
This invention relates to a piperazine derivative having the formula (I), wherein R' is selected from -H, -COOH and -CONH2; Ft" is selected from -H, -COOH and -CONH2 with the proviso that when R' is -COOH or -CONH2 then R" is not -COOH or -CONH2, and when R" is -COOH or -CONH2 then R' is not -COOH or -CONH2; A is selected from -(CH2)3-, -(CH2)2CH(OH)-, -CH2-CH=CH- (cis and trans), (a); B is selected from -(CH2)n-, -(CH2)nO-, -(CH2)nS- and -(CH2)n-CH=CH- (cis and trans), (b); and wherein n = 1 -4; and Y is selected from C1-C7 alkyl (straight or branched), C5-C6 cycloalkyi optionally substituted with one or more halogens, thiophene or phenyl optionally substituted with one or more halogens or -C(hal)3 wherein "hal" denotes a halogen, or a pharmaceutically acceptable salt thereof.
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
The present disclosure relates to system applications of multicore optical fibers. One embodiment relates to a base transceiver station for a wireless telecommunication system comprising a plurality of antenna units arranged in a MIMO configuration and adapted for transmission and/or reception of radio-frequency signals, an optical transmitter in the form of an electro-optic conversion unit for each of said plurality of antenna units, each electro-optic conversion unit adapted for converting an RF signal into an optical signal, a plurality of a single core optical fibers for guiding the optical signals, and at least one first space division multiplexing (SDM) unit adapted for multiplexing said single core optical fibers into respective individual cores of a multicore fiber, or into respective individual modes of a multimode fiber.
H04B 7/06 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
H04B 10/2575 - Radio sur fibre, p. ex. signal radio modulé en fréquence sur une porteuse optique
40.
GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY
The present invention relates to a composition comprising: a. non-water soluble carbohydrates b. a contrast agent for imaging, wherein at least 60% of the contrast agent remains within 10 cm from the injection site after 24h, for use in local co-administration into a human or animal body, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration.
A61K 49/04 - Préparations de contraste pour rayons X
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a composition for use as controlled release of at least one active pharmaceutical ingredient that modulates an immunogenic response in a human or animal body, said composition comprising non-water soluble carbohydrates and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to an all-optical pressure sensor comprising a waveguide accommodating a distributed Bragg reflector. Pressure sensing can then be provided by utilizing effective index modulation of the waveguide and detection of a wavelength shift of light reflected from the Bragg reflector. Sound sensing may also be provided thereby having an all-optical microphone. One embodiment of the invention relates to an optical pressure sensor comprising at least one outer membrane and a waveguide, the waveguide comprising at least one core for confining and guiding light, at least one distributed Bragg reflector located in said at least one core, and at least one inner deflecting element forming at least a part of the core, wherein the pressure sensor is configured such that the geometry and/or dimension of the at least one core is changed when the at least one outer membrane is submitted to pressure.
G01L 9/00 - Mesure de la pression permanente, ou quasi permanente d’un fluide ou d’un matériau solide fluent par des éléments électriques ou magnétiques sensibles à la pressionTransmission ou indication par des moyens électriques ou magnétiques du déplacement des éléments mécaniques sensibles à la pression, utilisés pour mesurer la pression permanente ou quasi permanente d’un fluide ou d’un matériau solide fluent
G01L 23/16 - Dispositifs ou appareils pour la mesure ou l'indication ou l'enregistrement des changements, rapides, tels que des oscillations, de la pression des vapeurs, des gaz ou des liquidesIndicateurs pour déterminer le travail ou l'énergie des moteurs à vapeur, à combustion interne ou à autres pressions de fluides à partir de la condition du fluide moteur mis en œuvre électriquement par des moyens photo-électriques
H04R 23/00 - Transducteurs autres que ceux compris dans les groupes
The present invention relates to a method for manufacturing enantiomerically pure (13R)-manoyl oxide, said method comprising the steps of contacting geranylgeranyl diphosphate (GGPP) with a class II diterpene synthase to obtain labd-13-en-8,15-diol diphosphate (LPP), and then contacting the LPP with a class I diterpene synthase to obtain (13R)-manoyl oxide. The invention further relates to (13R)-manoyl oxide obtained by the method of the invention.
C12P 17/02 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle
C07D 311/00 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, condensés avec d'autres cycles
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
The present disclosure relates to a cooling system comprising an active magnetic regenerator having a cold side and a hot side, a hot side heat exchanger connected to the hot side of the magnetic regenerator, one or more cold side heat exchangers, and a cold store reservoir comprising a volume of heat transfer fluid and connected between said one or more cold side heat exchangers and the cold side of the magnetic regenerator, wherein the cooling system is configured to provide a first flow cycle of said heat transfer fluid between the cold store reservoir, the magnetic regenerator and the hot side heat exchanger adapted to transfer thermal energy from the cold store reservoir to the hot side heat exchanger, and at least a second flow cycle of said heat transfer fluid between the cold store reservoir and said one or more cold side heat exchangers adapted to transfer thermal energy from said one or more cold side heat exchangers to the cold store reservoir.
The present invention relates to an all-optical sensor utilizing effective index modulation of a waveguide and detection of a wavelength shift of reflected light and a force sensing system accommodating said optical sensor. One embodiment of the invention relates to a sensor system comprising at least one multimode light source, one or more optical sensors comprising a multimode sensor optical waveguide accommodating a distributed Bragg reflector, at least one transmitting optical waveguide for guiding light from said at least one light source to said one or more multimode sensor optical waveguides, a detector for measuring light reflected from said Bragg reflector in said one or more multimode sensor optical waveguides, and a data processor adapted for analyzing variations in the Bragg wavelength of at least one higher order mode of the reflected light.
G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p. ex. par l'analyse des contraintes par photo-élasticité
G01L 11/02 - Mesure de la pression permanente, ou quasi permanente d'un fluide ou d'un matériau solide fluent par des moyens non prévus dans les groupes ou par des moyens optiques
G02B 6/10 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques
47.
WAVEGUIDE VOLUME PROBE FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY
The present disclosure relates to a probe for use within the field of nuclear magnetic resonance, such as magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS)). One embodiment relates to an RF probe for magnetic resonance imaging and/or spectroscopy comprising a conductive non-magnetic hollow waveguide having an internal volume and at least one open end, one or more capacitors and at least a first conductive non-magnetic wire, wherein said first conductive wire connects at least one of said one or more capacitors to opposite walls of one open end of the waveguide and wherein said first conductive wire and said one or more capacitors are located outside of said internal volume, wherein the internal volume of the hollow waveguide defines an imaging volume or sample volume.
The invention regards a flow meter for ultrasonically measuring the flow velocity of fluids comprising a duct having a flow channel with an internal cross section comprising variation configured to generate at least one acoustic resonance within the flow channel for a specific ultrasonic frequency, and at least two transducers for generating and sensing ultrasonic pulses, configured to transmit ultrasonic pulses at least at said specific ultrasonic frequency into the flow channel such that the ultrasonic pulses propagate through a fluid flowing in the flow channel, wherein the flow meter is configured to determine the flow velocity of the fluid flowing in the flow channel based on a change in transit time, phase and/or pulse such as amplitude and/or form, of the ultrasonic pulses.
G01F 1/66 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en mesurant la fréquence, le déphasage, le temps de propagation d'ondes électromagnétiques ou d'autres types d'ondes, p. ex. en utilisant des débitmètres à ultrasons
The present invention relates to a multiplex editing system. The system allows multiple editing of nucleic acid sequences such as genomic sequences, such as knockins of genes of interest in a genome, knockouts of genomic sequences and/or allele replacement. Also provided herein are a method for editing nucleic acids and a cell comprising a stably integrated endonuclease.
The present invention relates to a novel process for separation of heavy metals from a suspension comprising heavy metal containing particulate material, in which process the heavy metals are removed by use of the electrodialytic remediation set-up. The novel process of the present invention may also be used for recovery of phosphorous in cases where the particulate material also comprises phosphorous in addition to heavy metals. The present invention also relates to the electrochemical cell for use in performing the novel process and to the use of the novel process for separation of heavy metals from the heavy metal containing particulate material.
C02F 1/469 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par séparation électrochimique, p. ex. par électro-osmose, électrodialyse, électrophorèse
C02F 11/00 - Traitement des boues d'égoutDispositifs à cet effet
B09C 1/08 - Régénération de sols pollués par des procédés chimiques
The present invention provides a method for developing predictive models of ion channel inhibition by use of a training set of compounds selected from acidic and/or zwitterionic compounds, methods for predicting of ion channel inhibition of compounds selected from acidic and/or zwitterionic compounds, and computer-assisted methods of the above. More specifically the present invention relates to methods for prediction of h ERG inhibition, which is particularly useful for the screening of drugs for cardiac toxicity.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
The present disclosure relates to system applications of multicore optical fibers. One embodiment relates to a base transceiver station for a wireless telecommunication system comprising a plurality of antenna units arranged in a MIMO configuration and adapted for transmission and/or reception of radio-frequency signals, an optical transmitter in the form of an electro-optic conversion unit for each of said plurality of antenna units, each electro-optic conversion unit adapted for converting an RF signal into an optical signal, a plurality of a single core optical fibers for guiding the optical signals, and at least one first space division multiplexing (SDM) unit adapted for multiplexing said single core optical fibers into respective individual cores of a multicore fiber, or into respective individual modes of a multimode fiber.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
A61K 38/00 - Préparations médicinales contenant des peptides
C07D 487/00 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
The present invention relates to a novel non-platinum metal catalyst material for use in low temperature fuel cells and electrolysers and to fuel cells and electrolysers comprising the novel non-platinum metal catalyst material. The present invention also relates to a novel method for synthesizing the novel non-platinum metal catalyst material.
A yeast cell havinga reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has at least one exogenous gene encoding NADP dependent GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH, wherein combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.
Cells and cell cultures are provided that have improved tolerance to 3-hydroxypropionic acid (3HP). Genetic modifications to provide a mutated or overexpressed SFA1 gene or other enhancement of 3HP detoxification via a glutathione- dependent dehydrogenase reaction, including medium supplementation with glutathione, may be combined with a 3HP producing metabolic pathway.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
The present invention relates to the field of filtering, more precisely the present invention concerns an apparatus and a method for the separation of dry matter from a medium and the use of said apparatus. One embodiment discloses an apparatus for the separation of dry matter from a medium, comprising a pressure regulated separation chamber defined, in cross section, by a plurality of rollers mounted between opposing sidewalls, each of said rollers having a shaft adapted to be engaged with the sidewalls, a filter arranged so that it passes between at least one set of said rollers consisting of a pore roller and one other roller, means for establishing a pressure difference across the filter, means for passing filter and filter cake through the set of rollers, and a closure mechanism configured to control the transverse tension between the rollers.
B01D 33/044 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à bandes filtrantes ou analogues supportées par des cylindres perméables pour la filtration
B01D 33/073 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à surfaces filtrantes rotatives cylindriques, p. ex. tambours creux agencés pour la filtration à courant dirigé vers l'intérieur
B01D 33/37 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration avec plusieurs éléments de filtration caractérisés par leur agencement relatif montés en parallèle
B01D 33/64 - Manipulation du gâteau de filtration dans le filtre pour des raisons autres que la régénération pour le séchage par compression
The present invention relates to an all-optical pressure sensor comprising a waveguide accommodating a distributed Bragg reflector. Pressure sensing can then be provided by utilizing effective index modulation of the waveguide and detection of a wavelength shift of light reflected from the Bragg reflector. Sound sensing may also be provided thereby having an all-optical microphone. One embodiment of the invention relates to an optical pressure sensor comprising at least one outer membrane and a waveguide, the waveguide comprising at least one core for confining and guiding light,at least one distributed Bragg reflector located in said at least one core, and at least one inner deflecting element forming at least a part of the core,wherein the pressure sensor is configured such that the geometry and/or dimension of the at least one core is changed when the at least one outer membrane is submitted to pressure.
G01L 9/00 - Mesure de la pression permanente, ou quasi permanente d’un fluide ou d’un matériau solide fluent par des éléments électriques ou magnétiques sensibles à la pressionTransmission ou indication par des moyens électriques ou magnétiques du déplacement des éléments mécaniques sensibles à la pression, utilisés pour mesurer la pression permanente ou quasi permanente d’un fluide ou d’un matériau solide fluent
G01L 23/16 - Dispositifs ou appareils pour la mesure ou l'indication ou l'enregistrement des changements, rapides, tels que des oscillations, de la pression des vapeurs, des gaz ou des liquidesIndicateurs pour déterminer le travail ou l'énergie des moteurs à vapeur, à combustion interne ou à autres pressions de fluides à partir de la condition du fluide moteur mis en œuvre électriquement par des moyens photo-électriques
The present invention provides methods of upgrading of a CO2-containing fuel gas comprising the use of anaerobic succinic acid-producing microorganisms. Thus, the present invention provides a method for simultaneous upgrading of a CO2-containing fuel gas and biosuccinic acid production.
The invention provides a magnetocaloric heat pump device, comprising a magnetocaloric bed; a magnetic field source, the magnetocaloric bed and the magnetic field source being arranged to move relative to each other so as to generate a magnetocaloric refrigeration cycle within the heat pump, wherein the magnetic field source includes both a permanent magnet and an electromagnet.
The present invention relates to a novel alloy catalyst material for use in the synthesis of hydrogen peroxide from oxygen and hydrogen, or from oxygen and water. The present invention also relates to a cathode and an electrochemical cell comprising the novel catalyst material, and the process use of the novel catalyst material for synthesising hydrogen peroxide from oxygen and hydrogen, or from oxygen and water.
The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
In a method for performing a refractive index based measurement of a property of a fluid such as chemical composition or temperature, a chirp in the local spatial frequency of interference fringes of an interference pattern is reduced by mathematical manipulation of the recorded light intensity in the interference pattern or by the physical positioning and arrangement of a detector used for capturing the interference pattern.
In a method for performing a refractive index based measurement of a property of a fluid such as chemical composition or temperature by observing an apparent angular shift in an interference fringe pattern produced by back or forward scattering interferometry, ambiguities in the measurement caused by the apparent shift being consistent with one of a number of numerical possibilities for the real shift which differ by 2n are resolved by combining measurements performed on the same sample using light paths therethrough of differing lengths.
A refractive index based measurement of a property of a fluid is measured in an apparatus comprising a variable wavelength coherent light source (16), a sample chamber (12), a wavelength controller (24), a light sensor (20), a data recorder (26) and a computation apparatus (28), by - directing coherent light having a wavelength along an input light path, - producing scattering of said light from each of a plurality of interfaces within said apparatus including interfaces between said fluid and a surface bounding said fluid, said scattering producing an interference pattern formed by said scattered light, - cyclically varying the wavelength of said light in said input light path over a 1 nm to 20nm wide range of wavelengths a rate of from 10Hz to 50 KHz, - recording variation of intensity of the interfering light with change in wavelength of the light at an angle of observation, and - calculating a said property from said variation.
The present invention relates to a filtering apparatus and method for mixing a compound of solid and fluid phases, separating the phases and/or extracting fluid from the compound. One embodiment of the invention discloses a filtering apparatus comprising a first filter section accommodating a first group of filter members, and a second filter section accommodating a second group of filter members, a piping system providing pipelined fluid communication between the filter sections and between a filter section and said filter section's corresponding group of filter members, the piping system configured such that the filter members form filtered fluid openings of the filtering apparatus, and circulation means, such as a pump, configured for passing fluid in a forward flow and/or in a reverse flow between the filter sections. In particular the invention may be used for the mashing process in a beer brewing procedure.
B01D 33/37 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration avec plusieurs éléments de filtration caractérisés par leur agencement relatif montés en parallèle
B01D 33/41 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration avec plusieurs éléments de filtration caractérisés par leur agencement relatif montés en série
B01D 33/35 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration avec plusieurs éléments de filtration caractérisés par leur agencement relatif
B01D 29/50 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants à plusieurs éléments filtrants caractérisés par leur agencement relatif
B01D 29/52 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants à plusieurs éléments filtrants caractérisés par leur agencement relatif montés en parallèle
B01D 29/56 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants à plusieurs éléments filtrants caractérisés par leur agencement relatif montés en série
C12C 11/11 - Traitements après fermentation, p. ex. carbonatation ou concentration
C12C 7/165 - Clarification du moût par filtrage à travers des filtres à trempe
B01D 33/073 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à surfaces filtrantes rotatives cylindriques, p. ex. tambours creux agencés pour la filtration à courant dirigé vers l'intérieur
B01D 33/11 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à surfaces filtrantes rotatives cylindriques, p. ex. tambours creux agencés pour la filtration à courant dirigé vers l'extérieur
B01D 29/11 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants avec des éléments filtrants en forme de sac, de cage, de tuyau, de tube, de manchon ou analogue
B01D 29/15 - Éléments filtrants avec des supports agencés pour la filtration à courant dirigé vers l'intérieur
B01D 29/23 - Éléments filtrants avec des supports agencés pour la filtration à courant dirigé vers l'extérieur
67.
DATABASE-DRIVEN PRIMARY ANALYSIS OF RAW SEQUENCING DATA
The present invention relates to methods for identifying the source of a biological sequence containing sample from raw sequencing reads. The method may be used to identify the source of unknown DNA and can be used for diagnostic, biodefense, food safety and quality, and hygiene applications. In another aspect the invention relates to a database of reference sequences which can be used in the method of the invention.
G06F 19/22 - pour la comparaison de séquences impliquant des nucléotides ou des acides aminés, p.ex. recherche d'homologie, identification de motifs ou de polymorphismes de nucléotides simples [SNP] ou alignement de séquences
A genetically modified Saccharomyces cerevisiae comprising an active fermentation pathway producing 3-HP expresses an exogenous gene expressing the aminotransferase YhxA from Bacillus cereus AH1272 catalysing a transamination reaction between beta-alanine and pyruvate to produce malonate semialdehyde. The yeast may also express a 3-hydroxyisobutyrate dehydrogenase (HIBADH) and a 3-hydroxypropanoate dehydrogenase (3-HPDH) and aspartate 1-decarboxylase. Additionally the yeast may express pyruvate carboxylase and aspartate aminotransferase.
A method of conducting radiofluorination of a substrate, comprising the steps of: (a) contacting an aqueous solution of [18F] fluoride with a polymer supported phosphazene base for sufficient time for trapping of [18F] fluoride on the polymer supported phosphazene base; and (b) contacting a solution of the substrate with the polymer supported phosphazene base having [18F] fluoride trapped thereon obtained in step (a) for sufficient time for a radiofluorination reaction to take place; an apparatus for conducting radiofluorination; use of the apparatus; and an apparatus for production of a dose of a radiotracer for administration to a patient.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
70.
SOLID OXIDE CELL OXYGEN ELECTRODE WITH ENHANCED DURABILITY
The present invention provides various methods of producing a solid oxide cell with an enhanced durability. Dopants are provided at the interface of the electrode comprising LSM and electrolyte and prevent especially the diffusion of Mn from the electrode layer into the electrolyte, stabilizing the LSM and thereby preventing the formation of unwanted degradation products.
IBC - DEPARTMENT OF INTERNATIONAL BUSINESS COMMUNICATION (Danemark)
TECHNICAL UNIVERSITY OF DENMARK (Danemark)
Inventeur(s)
Glückstad, Fumiko Kano
Mørup, Morten
Herlau, Tue
Schmidt, Mikkei, N.
Abrégé
The present invention relates to a method, computer program and system for inferring relations between cultural specific concepts (CSC) in two cultures at least comprising the steps of - extracting and listing said cultural specific concepts (CSCs) and features of said CSCs from at least a first corpora belonging to a first culture and a second corpora belonging to a second culture, - applying a algorithm to infer relations between said CSCs in the first and the second corpora.
The present invention relates to a system and a method for detection of abnormal motor activity during REM sleep, and further to systems and method for assisting in detecting neurodegenerative disorders such as Parkinson's. One embodiment relates to a method for detection of abnormal motor activity during REM sleep comprising the steps of: performing polysomnographic recordings of a sleeping subject, thereby obtaining one or more electromyography (EMG) derivations, preferably surface EMG recordings, and one or more EEG derivations, and/or one or more electrooculargraphy (EOG) derivations, detecting one or more REM sleep stages, preferably based on the one or more EEG and/or EOG derivations, determining the level of muscle activity during the one or more REM sleep stages based on the one or more EMG derivations, wherein a subject having an increased level of muscle activity during REM sleep compared to one or more normal subjects has abnormal motor activity during REM sleep.
The present invention relates to an all-optical sensor utilizing effective index modulation of a waveguide and detection of a wavelength shift of reflected light and a force sensing system accommodating said optical sensor. One embodiment of the invention relates to a sensor system comprising at least one multimode light source, one or more optical sensors comprising a multimode sensor optical waveguide accommodating a distributed Bragg reflector, at least one transmitting optical waveguide for guiding light from said at least one light source to said one or more multimode sensor optical waveguides, a detector for measuring light reflected from said Bragg reflector in said one or more multimode sensor optical waveguides, and a data processor adapted for analyzing variations in the Bragg wavelength of at least one higher order mode of the reflected light.
G01L 11/02 - Mesure de la pression permanente, ou quasi permanente d'un fluide ou d'un matériau solide fluent par des moyens non prévus dans les groupes ou par des moyens optiques
G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p. ex. par l'analyse des contraintes par photo-élasticité
The present invention concerns a novel internal reference electrode as well as a novel sensing electrode for an improved internal reference oxygen sensor and the sensor employing same.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
A61K 38/00 - Préparations médicinales contenant des peptides
C07D 487/00 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes
The present invention relates to methods for predicting response of a cancer in a subject to anti-cancer therapies based upon a determination and analysis of a chromosomal aberration score, such as the number of allelic imbalance or the number of telomeric allelic imbalance in the chromosomes of the human genome.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
77.
AN ILLUMINATION SYSTEM FOR ENDOSCOPIC APPLICATIONS
The present disclosure relates to an illumination system for endoscopic applications comprising at least one substantially monochromatic light source having a predefined central wavelength between 400 and 500 nm or between 500 and 550 nm, an optical transmission path adapted to guide light emanating from the light source to an endoscopic region of examination, and an optical band-rejection filter, wherein the illumination system is adapted to illuminate at least a part of the region of examination by generating autofluorescence in surrounding tissue, and the band-rejection filter is adapted to attenuate at least said light source wavelength to a viewer and wherein said light source is the single light source in the illumination system. A further embodiment relates to an endoscope for examining a body cavity comprising tissue, the endoscope comprising a source of light consisting of a substantially monochromatic light source having a predefined central wavelength between 400 and 550 nm, means for guiding light from the substantially monochromatic light source towards at least a part of the tissue, and at least one band-rejection filter adapted to attenuate at least said central wavelength, wherein the substantially monochromatic light source is configured to generate autofluorescence in the irradiated tissue such that the irradiated tissue is observable, and wherein the endoscope is configured to display at least a part of the irradiated tissue through said band-rejection filter. A system for photodynamic diagnosis and/or therapy of bladder cancer is further disclosed herein.
A61B 1/307 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'appareil urinaire, p. ex. urétroscopes, cystoscopes
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
78.
A MODIFIED ANODE/ELECTROLYTE STRUCTURE FOR A SOLID OXIDE ELECTROCHEMICAL CELL AND A METHOD FOR MAKING SAID STRUCTURE
A novel modified anode/electrolyte structure for a solid oxide electrochemical cell is an assembly comprising (a) an anode consisting of a backbone of electronically conductive perovskite oxides selected from the group of doped strontium titanates and mixtures thereof, (b) a scandia and yttria-stabilised zirconium oxide electrolyte and (c) a metallic and/or a ceramic electrocatalyst in the shape of interlayers incorporated in the interface between the anode and the electrolyte. This assembly is first sintered at a given temperature and then at a lower temperature in reducing gas mixtures. These heat treatments resulted in a distribution of the metallic and/or ceramic interlayers in the electrolyte/anode backbone junction taking place. The structure is prepared by (a) depositing a ceramic interlayer onto one side of the electrolyte, (b) optionally applying a metallic interlayer thereon, (c) repeating steps (a) and (b), (d) applying a layer of the selected anode backbone onto the electrolyte with applied interlayers, (e) sintering the raw assembly and (f) infiltrating the electrocatalyst precursor into the sintered assembly and heat treating the assembly to incorporate additional electrocatalyst into the anode backbone.
H01M 4/90 - Emploi de matériau catalytique spécifié
C04B 35/00 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques
79.
METHODS AND APPARATUS FOR HYDROGEN BASED BIOGAS UPGRADING
The present invention relates to an anaerobic process for biogas upgrading and hydrogen utilization comprising the use of acidic waste as co-substrate.In this process,H2 and CO2 will be converted to CH4, which will result in lower CO2 content in the biogas. The invention relates to both in situ and ex situ methods of biogas upgrading. The invention further relates to a bioreactor comprising hollow fibre membranes.
A high performance anode (fuel electrode) for use in a solid oxide electrochemical cell is obtained by a process comprising the steps of (a) providing a suitably doped, stabilized zirconium oxide electrolyte, such as YSZ,ScYSZ, with an anode side having a coating of electronically conductive perovskite oxides selected from the group consisting of niobium-doped strontium titanate, vanadium-doped strontium titanate, tantalum-doped strontium titanate and mixtures thereof, thereby obtaining a porous anode backbone, (b) sintering the coated electrolyte at a high temperature, such as 1200°C in a reducing atmosphere, for a sufficient period of time, (c) effecting a precursor infiltration of a mixed catalyst into the backbone, said catalyst comprising a combination of noble metals Pd or Pt or Pd or Ru and Ni with rare earth metals, such as Ce or Gd, said infiltration consisting of (1) infiltration of Pd, Ru and CGO containing chloride/nitrate precursors and (2) infiltration of Ni and CGO containing nitrate precursors, and (d) subjecting the resulting structure of step (c) to heat treatments, including heat treatments in several steps with infiltration.
H01M 4/90 - Emploi de matériau catalytique spécifié
C04B 35/00 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques
81.
METHOD AND SYSTEM FOR PURIFICATION OF GAS/LIQUID STREAMS FOR FUEL CELLS OR ELECTROLYSIS CELLS
The present invention provides in embodiments a method for purification of inlet gas/liquid streams in a fuel cell or electrolysis cell, the fuel cell or electrolysis cell comprising at least a first electrode, an electrolyte and a second electrode, the method comprising the steps of: - providing at least one scrubber in the gas/liquid stream at the inlet side of the first electrode of the fuel cell or electrolysis cell; and/or providing at least one scrubber in the gas/liquid stream at the inlet side of the second electrode of the fuel cell or electrolysis cell; and - purifying the gas/liquid streams towards the first and second electrode; wherein the at least one scrubber in the gas/liquid stream at the inlet side of the first electrode and/or the at least one scrubber in the gas/liquid stream at the inlet side of the second electrode comprises a material suitable as an electrolyte material and a material suitable as an electrode material, and wherein the material suitable as an electrolyte material and a material suitable as an electrode material form triple phase boundaries similar to or identical to the triple phase boundaries of the electrode for which the gas/liquid stream is purified with the at least one scrubber, with the proviso that the fuel cell or electrolysis cell is not a solid oxide cell.
H01M 8/06 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
82.
FILTERING APPARATUS AND METHOD FOR MIXING, EXTRACTION AND/OR SEPARATION
The present invention relates to a filtering apparatus and method for mixing a compound of solid and fluid phases, separating the phases and/or extracting fluid from the compound. One embodiment of the invention discloses a filtering apparatus comprising a first filter section accommodating a first group of filter members, and a second filter section accommodating a second group of filter members,a piping system providing pipelined fluid communication between the filter sections and between a filter section and said filter section's corresponding group of filter members, the piping system configured such that the filter members form filtered fluid openings of the filtering apparatus, and circulation means, such as a pump, configured for passing fluid in a forward flow and/or in a reverse flow between the filter sections. In particular the invention may be used for the mashing process in a beer brewing procedure.
B01D 33/15 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à surfaces filtrantes rotatives planes
B01D 33/37 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration avec plusieurs éléments de filtration caractérisés par leur agencement relatif montés en parallèle
A23L 1/221 - Epices, agents aromatiques ou condiments naturels; Leurs extraits
B01F 7/00 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins
B01D 29/11 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants avec des éléments filtrants en forme de sac, de cage, de tuyau, de tube, de manchon ou analogue
B01D 29/52 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants à plusieurs éléments filtrants caractérisés par leur agencement relatif montés en parallèle
B01D 29/70 - Régénération de la substance filtrante dans le filtre par des forces générées par un mouvement de l'élément filtrant
B01D 29/94 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants comportant des dispositifs d'alimentation ou d'évacuation d'évacuation du gâteau de filtration, p. ex. goulottes
B01D 35/147 - Soupapes de dérivation ou de sécurité
83.
A LIQUID FILLED LIGHT DISTRIBUTOR AND A METHOD OF USE
The present invention relates to liquid filled light distributor comprising an elongated tubular body with a tube wall defining an in inner lumen filled with a liquid, said tubular body having -a proximal end closed by first closing means -a distal end closed by second closing means. Wherein the proximal end is arranged to be in optical communication with a light source and wherein the refractive index of the tube wall is n1 and the refractive index of the fluid is n2 and n1/n2 <1 so that light from the light source travels along the longitudinal direction of the tubular body and that a part of the light is emitted through the tube wall along at least a part of the tubular body. Further a method of use for the liquid filled light distributor is provided.
A61L 2/10 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations des ultraviolets
The present invention relates to a flange for sampling a liquid flow from a substantially vertical liquid flow path comprising a trench located on the flange rim and adapted for collecting and/or housing a liquid sample and a channel for collecting or extracting said liquid sample, said channel extending transversely through at least a part of the side of the flange in liquid communication with said trench.
The present invention concerns a structure useful for producing a thermoelectric generator, a thermoelectric generator comprising same and a method for producing same. A method for producing a structure useful for producing a thermoelectric generator, wherein the structure comprises at least one stripe of a n-type and at least one stripe of a p-type material, either separated by a stripe of an insulating material, or provided spatially separated on an insulating material, and comprising stripes of conductive material each connecting one n-type stripe with one p-type stripe, and not in electrical contact with each other, wherein the structure is free from polymeric substrates, wherein the method comprises the steps of co-forming the at least one stripe of a n-type and at least one stripe of a p-type material in a single manufacturing step; and forming connections between the at least one stripe of a n-type and at least one stripe of a p- type material by means of stripes of conductive material. The structure useful for producing a thermoelectric generator is obtainable by the above method. The thermoelectric generator comprises at least one such structure.
H01L 35/22 - Emploi d'un matériau spécifié pour les bras de la jonction utilisant des compositions inorganiques comprenant des composés contenant du bore, du carbone, de l'oxygène ou de l'azote
H01L 35/32 - DISPOSITIFS À SEMI-CONDUCTEURS; DISPOSITIFS ÉLECTRIQUES À L'ÉTAT SOLIDE NON PRÉVUS AILLEURS - Détails fonctionnant exclusivement par effet Peltier ou effet Seebeck caractérisés par la structure ou la configuration de la cellule ou du thermocouple constituant le dispositif
H01L 35/34 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
86.
SINTERING ADDITIVES FOR CERAMIC DEVICES OBTAINABLE IN A LOW pO2 ATMOSPHERE
The present invention provides a method for producing a ceramic device in a low pO2 atmosphere, comprising the steps of: - providing a composition comprising a base material and a transition metal; wherein the base material for the first layer is selected from the group consisting of zirconate, cerate, titanate, lanthanate, aluminate, doped zirconia and/or doped ceria, wherein the dopants are selected from the group of Ca, Ga, Sc, Y, and lanthanide elements; - forming a first layer of said composition, wherein said first layer is an electrolyte layer; - forming at least one electrode layer or electrode precursor layer on one side or both sides of said first layer; and - sintering the multilayer structure in a low p02 atmosphere; characterized in that: the amount of the transition metal is from 0.01 to 4 mol%, based on the composition of the first layer; the oxygen partial pressure p02 is 10"14 Pa or less; and the sintering temperature is in the range of from 700 to 1600°C.
C04B 35/462 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base d'oxydes de titane ou de titanates à base de titanates
C04B 35/50 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de composés de terres rares
C04B 35/44 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base d'aluminates
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
C23C 28/00 - Revêtement pour obtenir au moins deux couches superposées, soit par des procédés non prévus dans un seul des groupes principaux , soit par des combinaisons de procédés prévus dans les sous-classes et
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
TECHNICAL UNIVERSITY OF DENMARK (Danemark)
Inventeur(s)
Studt, Felix
Abild-Pedersen, Frank
Norskov, Jens
Dahl, Soren
Sharafutdinov, Irek
Elkjaer, Christian
Abrégé
A catalytic composition is provided for methanol production. The composition includes an alloy of at least two different metals M and M', where M is selected from Ni, Pd, Ir, and Ru, and M' is selected from Ga, Zn, and Al. A molar ratio of M to M' is in the range of 1:10 to 10:1, and the alloy is configured to catalyze a reduction of CO2 to methanol.
A photovoltaic cell module comprising at least two serially connected photovoltaic cells on a common substrate, wherein the cells each comprise a first electrode layer, a first charge selective layer, a light harvesting layer which comprises an organic conjugated polymer, and a second charge selective layer that selects for an opposite charge to the first charge selective layer, wherein the first electrode layers for each cell are formed such that the first electrode layer of one cell has no direct electrical connection to the first electrode layer of any other cell, and the second charge selective layer is formed such that the second charge selective layer of one cell has no direct electrical connection to the second charge selective layer of any other cell, and wherein the light-harvesting layer is formed such that it is common to at least one pair of adjacent cells of the module; wherein, for the at least one pair of adjacent cells to which the light harvesting layer is common, a metal layer is formed such that an electrical connection is established between the second charge selective layer of a first one of the at least one pair of adjacent cells and the first electrode layer of a second cell of the pair, which connection is made through the light harvesting layer common to the at least one pair of cells, without forming an electrical connection with the first electrode of the first cell or the second charge selective layer of the second cell; and a method of making such a photovoltaic cell module.
H01L 51/42 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement
H01L 27/30 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des composants qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux avec des composants spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement
A container assembly for the containment of fluids or solids under a pressure different from the ambient pressure comprising a container (2) comprising an opening and an annular sealing, a lid (3) comprising a central portion (5) and engagement means (7) for engaging the annular flange, and sealing means (10) wherein the engagement means (7) is adapted, via the sealing means, to seal the opening when the pressure of the container assembly differs from the ambient pressure in such a way that the central portion (5) flexes in the axial direction which leads to a radial tightening of the engagement means (7) to the container, wherein the container further comprises locking means (12) that can be positioned so that the central portion is hindered from flexing in at least one direction.
The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides,for example 61Cu and 64Cu copper isotopes. The invention further relates to a novel method for loading delivery systems, such as liposome compositions, with metal entities such as radionuclides, and the use of liposomes for targeted diagnosis and treatment of a target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
91.
SOLID OXIDE CELL STACK AND METHOD FOR PREPARING SAME
A method for producing and reactivating a solid oxide cell stack structure by providing a catalyst precursor in at least one of the electrode layers by impregnation and subsequent drying after the stack has been assembled and initiated. Due to a significantly improved performance and an unexpected voltage improvement this solid oxide cell stack structure is particularly suitable for use in solid oxide fuel cell (SOFC) and solid oxide electrolysing cell (SOEC) applications.
The present invention relates to a novel anaerobic, extreme thermophilic, ethanol high- yielding bacterium. The invention is based on the isolation of the bacterial strain referred to herein as "DTU01", which produces ethanol as the main fermentation product, followed by acetate and lactate. The isolated organism is an extremely interesting and very promising organism for the establishment of a sustainable bioethanol production process. The invention further relates to a method for producing a fermentation product such as ethanol.
The present invention relates to methods for diagnosing transplant rejection, or a condition associated with transplant rejection, such as, primary graft dysfunction in a subject, to antigen probe arrays for performing such a diagnosis, and to antigen probe sets for generating such arrays.
The present invention provides: a method of preparing a coating ink for forming a zinc oxide electron transport layer, comprising mixing zinc acetate and a wetting agent in water or methanol; a coating ink comprising zinc acetate and a wetting agent in aqueous solution or methanolic solution; a method of preparing a zinc oxide electron transporting layer, which method comprises: i) coating a substrate with the coating ink of the present invention to form a film; ii) drying the film; and iii) heating the dry film to convert the zinc acetate substantially to ZnO; a method of preparing an organic photovoltaic device or an organic LED having a zinc oxide electron transport layer, the method comprising, in this order: a) providing a substrate bearing a first electrode layer; b) forming an electron transport layer according to the following method: i) coating a coating ink comprising an ink according to the present invention to form a film; ii) drying the film; iii) heating the dry film such that the zinc acetate is substantially converted to ZnO; c) forming an active layer; d) forming a hole transport layer; and e) forming a second electrode layer; and an optoelectronic device comprising an electron transporting layer comprising zinc oxide and a wetting agent.
The present invention relates to: a method of preparing a coating ink for forming a zinc oxide layer, which method comprises the steps of: a) mixing zinc acetate and AlOH (OAc)2 in water or methanol and b) filtering out solids; a coating ink comprising zinc acetate and AlOH (OAc)2 in aqueous or methanolic solution; a method of preparing a layer comprising zinc oxide, which method comprises: i) coating a substrate with the coating ink of the invention to form a film, ii) drying the film, and iii) heating the dry film to convert the zinc acetate substantially to ZnO; and a method of preparing an organic photovoltaic device or an organic LED having a polymer/fullerene active layer, the method comprising, in this order: a) providing a substrate bearing a first electrode layer, b) forming an electron transport layer according to the method of preparing a layer comprising zinc oxide according to the invention, c) forming an active layer, d) forming a hole transport layer, and e) forming a second electrode layer.
C23C 18/12 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtementDépôt par contact par décomposition thermique caractérisée par le dépôt sur des matériaux inorganiques, autres que des matériaux métalliques
H01L 51/42 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
A method of preparing an optoelectric device, comprising: (a) providing a substrate on which is formed a first electrode layer; (b) forming an electron transport layer according to the following method: i) forming a film of a coating ink comprising zinc acetate in aqueous solution; ii) drying the film; iii) heating the dry film such that the zinc acetate is substantially converted to ZnO; (c) forming an active layer according to either of the following methods: i) applying a coating ink comprising a light-harvesting polymer and a fullerene to the electron transport layer and drying the coating ink layer; or (ii) applying a coating ink comprising a soluble precursor of a light harvesting polymer, a fullerene and a solvent to the electron transport layer, drying the coating ink layer and treating the dried coating ink layer to convert the soluble precursor of a light-harvesting polymer into a light harvesting polymer that is substantially insoluble in the solvent comprised in the coating ink; (d) forming a hole transport layer on the active layer according to the following method: i) coating the active layer with a solution comprising a hole transporting compound, water and an alcohol to form a film; ii) drying the film to form a hole transport layer; (e) forming a second electrode layer on the hole transport layer.
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
98.
MORDENITE - TYPE ZEOLITE SCR CATALYSTS WITH IRON OR COPPER
Cu/mordenite catalysts were found to be highly active for the SCR of NO with NH3 and exhibited high resistance to alkali poisoning. Redox and acidic properties of Cu/mordenite were well preserved after poisoning with potassium unlike that of vanadium catalysts. Fe-mordenite catalysts also revealed much higher alkali resistivity than that of commercial V2O5/WO3-TiO2 (VWT) SCR catalyst which is currently used for NOx abatement in stationary installations. Unique support properties like high surface area and surface acidity, which are not available in the commercial VWT catalyst, seem to be essential requirements for the high alkali resistance. Mordenite-type zeolite based catalysts could therefore be attractive alternatives to conventional SCR catalysts for biomass fired power plant flue gas treatment.
The present invention relates to a method for producing one or more Monascus-like pigment composition from Penicillium species comprising: a) providing a cultivation medium comprising a high concentration of C-and N-sources and a high C/N molar ratio, b) adjusting pH to about 5 to 8, c) inoculating the cultivation medium with an inoculum of Penicillium to form a cultivation composition; d) cultivating the inoculated cultivation composition of (c); e) separating the one or more produced pigment compositions. The method of the invention may be used for producing Monascus-like pigment compositions for use as colouring agents in food items or non food items. The inventions further relates to Monascus-like pigment composition obtainable by a method of the inventions as well as use of the pigments.
The present invention relates to a method and nano-sized particles for image guided radiotherapy (IGRT) of a target tissue. More specifically, the invention relates to nano-sized particles comprising X-ray-imaging contrast agents in solid form with the ability to block x-rays, allowing for simultaneous or integrated external beam radiotherapy and imaging, e.g., using computed tomography (CT).
brevets
